New drug combo aims to ease sleep apnea
NCT ID NCT05350215
First seen Mar 05, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This early-phase study tests whether a combination of two drugs, atomoxetine and DAW2022, can reduce the severity of obstructive sleep apnea (OSA). Researchers will monitor 18 adults with moderate-to-severe OSA overnight to see if the drugs lower breathing interruptions and improve oxygen levels. The goal is to find a better-tolerated alternative to current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02135, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.